The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Fenobeta     propan-2-yl2-[4-(4- chlorophenyl)carbonylp...

Synonyms: Lipantil, Supralip, Controlip, Lipanthyl, Liparison, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lipantil


Psychiatry related information on Lipantil


High impact information on Lipantil

  • Among the more potent Abeta42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID [11].
  • In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein [12].
  • Nuclear run-on experiments demonstrated that the increase in human apo A-I and the decrease in mouse apo A-I gene expression after fenofibrate occurred at the transcriptional level [13].
  • Treatment with fenofibrate (0.5% wt/wt) for 7 d increased plasma human apo A-I levels up to 750% and HDL-cholesterol levels up to 200% with a shift to larger particles [13].
  • Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-II concentrations (0.34 +/- 0.11 to 0.45 +/- 0.17 grams/liter; P < 0.01) [14].

Chemical compound and disease context of Lipantil


Biological context of Lipantil


Anatomical context of Lipantil


Associations of Lipantil with other chemical compounds


Gene context of Lipantil


Analytical, diagnostic and therapeutic context of Lipantil


  1. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. De Vos, P., Lefebvre, A.M., Miller, S.G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L.G., Staels, B., Briggs, M.R., Auwerx, J. J. Clin. Invest. (1996) [Pubmed]
  2. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor. Thomas, J., Bramlett, K.S., Montrose, C., Foxworthy, P., Eacho, P.I., McCann, D., Cao, G., Kiefer, A., McCowan, J., Yu, K.L., Grese, T., Chin, W.W., Burris, T.P., Michael, L.F. J. Biol. Chem. (2003) [Pubmed]
  3. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Verg??s, B. Curr. Opin. Lipidol. (2006) [Pubmed]
  4. Lipid-lowering trials in diabetes. Betteridge, D.J. Curr. Opin. Lipidol. (2001) [Pubmed]
  5. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Koh, E.H., Kim, M.S., Park, J.Y., Kim, H.S., Youn, J.Y., Park, H.S., Youn, J.H., Lee, K.U. Diabetes (2003) [Pubmed]
  6. Hyperlipidemic dementia. Mas, J.L., Bousser, M.G., Lacombe, C., Agar, N. Neurology (1985) [Pubmed]
  7. Effect of fenofibrate on fatty liver in rats treated with alcohol. Tsutsumi And, M., Takase, S. Alcohol. Clin. Exp. Res. (2001) [Pubmed]
  8. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Levin, A., Duncan, L., Djurdjev, O., Shapiro, R.J., Frohlich, J., Belanger, A., Dumas, R., Ross, S. Clin. Nephrol. (2000) [Pubmed]
  9. Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb. Bertolini, S., Elicio, N., Daga, A., Degl'Innocenti, M.L., Balestreri, R., Fusi, M.G., Cotta Ramusino, A.M., Carozzi, A. Eur. J. Clin. Pharmacol. (1988) [Pubmed]
  10. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents. Haffner, S.M., Ashraf, T. Managed care interface. (2000) [Pubmed]
  11. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Kukar, T., Murphy, M.P., Eriksen, J.L., Sagi, S.A., Weggen, S., Smith, T.E., Ladd, T., Khan, M.A., Kache, R., Beard, J., Dodson, M., Merit, S., Ozols, V.V., Anastasiadis, P.Z., Das, P., Fauq, A., Koo, E.H., Golde, T.E. Nat. Med. (2005) [Pubmed]
  12. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.C., Najib, J., Maclouf, J., Tedgui, A. Nature (1998) [Pubmed]
  13. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J., Guillouzo, A., Fruchart, J.C., Rubin, E., Denèfle, P., Staels, B., Branellec, D. J. Clin. Invest. (1996) [Pubmed]
  14. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J.C., Staels, B., Auwerx, J. J. Clin. Invest. (1995) [Pubmed]
  15. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Seo, Y.H., Choi, I.S., Shin, E.K. J. Am. Coll. Cardiol. (2005) [Pubmed]
  16. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. Deighan, C.J., Caslake, M.J., McConnell, M., Boulton-Jones, J.M., Packard, C.J. J. Am. Soc. Nephrol. (2001) [Pubmed]
  17. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. Ogata, T., Miyauchi, T., Sakai, S., Takanashi, M., Irukayama-Tomobe, Y., Yamaguchi, I. J. Am. Coll. Cardiol. (2004) [Pubmed]
  18. Simvastatin, fenofibrate, and rhabdomyolysis. Jacob, S.S., Jacob, S., Williams, C., Deeg, M.A. Diabetes Care (2005) [Pubmed]
  19. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. Staels, B., Auwerx, J. Development (1992) [Pubmed]
  20. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts, G.F., Barrett, P.H., Ji, J., Serone, A.P., Chan, D.C., Croft, K.D., Loehrer, F., Johnson, A.G. Diabetes (2003) [Pubmed]
  21. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J.C., Auwerx, J., Staels, B. J. Biol. Chem. (1994) [Pubmed]
  22. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Forcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., Beylot, M. Diabetes (2002) [Pubmed]
  23. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Netik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G., Berger, J. Hum. Mol. Genet. (1999) [Pubmed]
  24. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. Vu-Dac, N., Gervois, P., Jakel, H., Nowak, M., Bauge, E., Dehondt, H., Staels, B., Pennacchio, L.A., Rubin, E.M., Fruchart-Najib, J., Fruchart, J.C. J. Biol. Chem. (2003) [Pubmed]
  25. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Park, C.W., Kim, H.W., Ko, S.H., Chung, H.W., Lim, S.W., Yang, C.W., Chang, Y.S., Sugawara, A., Guan, Y., Breyer, M.D. Diabetes (2006) [Pubmed]
  26. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. Lan, D., Silver, D.L. J. Biol. Chem. (2005) [Pubmed]
  27. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Kleemann, R., Verschuren, L., de Rooij, B.J., Lindeman, J., de Maat, M.M., Szalai, A.J., Princen, H.M., Kooistra, T. Blood (2004) [Pubmed]
  28. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators. Macdonald, N., Holden, P.R., Roberts, R.A. Cancer Res. (1999) [Pubmed]
  29. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.M., Winegar, D.A., Willson, T.M., Fruchart, J.C., Berge, R.K., Staels, B. J. Biol. Chem. (2000) [Pubmed]
  30. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Reifel-Miller, A., Otto, K., Hawkins, E., Barr, R., Bensch, W.R., Bull, C., Dana, S., Klausing, K., Martin, J.A., Rafaeloff-Phail, R., Rafizadeh-Montrose, C., Rhodes, G., Robey, R., Rojo, I., Rungta, D., Snyder, D., Wilbur, K., Zhang, T., Zink, R., Warshawsky, A., Brozinick, J.T. Mol. Endocrinol. (2005) [Pubmed]
  31. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., Kooistra, T. J. Biol. Chem. (2004) [Pubmed]
  32. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. Mandard, S., Zandbergen, F., Tan, N.S., Escher, P., Patsouris, D., Koenig, W., Kleemann, R., Bakker, A., Veenman, F., Wahli, W., Müller, M., Kersten, S. J. Biol. Chem. (2004) [Pubmed]
  33. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Guérin, M., Bruckert, E., Dolphin, P.J., Turpin, G., Chapman, M.J. Arterioscler. Thromb. Vasc. Biol. (1996) [Pubmed]
  34. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Grabacka, M., Plonka, P.M., Urbanska, K., Reiss, K. Clin. Cancer Res. (2006) [Pubmed]
  35. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. Duez, H., Chao, Y.S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C.A., Tedgui, A., Fruchart, J.C., Fiévet, C., Wright, S.D., Staels, B. J. Biol. Chem. (2002) [Pubmed]
  36. Isolation and characterization of a cDNA encoding rat liver cytosolic epoxide hydrolase and its functional expression in Escherichia coli. Knehr, M., Thomas, H., Arand, M., Gebel, T., Zeller, H.D., Oesch, F. J. Biol. Chem. (1993) [Pubmed]
  37. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. Nigro, J., Ballinger, M.L., Dilley, R.J., Jennings, G.L., Wight, T.N., Little, P.J. Diabetologia (2004) [Pubmed]
  38. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Canaple, L., Rambaud, J., Dkhissi-Benyahya, O., Rayet, B., Tan, N.S., Michalik, L., Delaunay, F., Wahli, W., Laudet, V. Mol. Endocrinol. (2006) [Pubmed]
WikiGenes - Universities